Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx Limited filings document an operating epigenetics diagnostics company with public-company disclosures centered on Nu.Q® assays, capital structure and exchange compliance. Recent 8-K reports and proxy materials cover shareholder votes on common-stock issuance capacity and reverse-stock-split authority, the effectiveness of a one-for-twenty reverse split, and amendments to the company’s certificate of incorporation.
The filing record also includes material-event reports on NYSE American continued-listing standards, annual financial-result updates, unregistered sales of equity securities, convertible-note share settlements, private placements and warrants. These documents describe governance approvals, security-holder rights, financing mechanics, listing-compliance matters and operating updates for Volition’s diagnostics and monitoring business.
VolitionRx held its Annual Meeting on June 18, 2025, where stockholders approved several significant proposals. The most notable change was the approval of a Certificate of Second Amendment to increase authorized shares from 175 million to 325 million shares of common stock ($0.001 par value).
Key meeting outcomes include:
- Election of eight board members, including CEO Cameron Reynolds, who received strong support with 36.1M votes
- Ratification of Sadler, Gibb & Associates as independent auditors with overwhelming approval (51.2M votes in favor)
- Approval of executive compensation through a non-binding advisory vote (34.4M votes in favor)
- Strong support for the share authorization increase with 49.4M votes in favor
The meeting had 51.6 million shares represented out of 100.7 million outstanding shares. The amendment became effective upon filing with Delaware's Secretary of State on June 18, 2025, marking a significant expansion in the company's potential capital structure.